A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
Checked against the public recordLast updated Apr 17, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Drug: BMS-986484; Biological: Nivolumab; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Fluorouracil; Drug: Calcium folinate
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN). * Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1). * Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. Exclusion Criteria: * History of or with active interstitial lung disease or pulmonary fibrosis. * Active, known, or suspected autoimmune disease. * Serious uncontrolled medical disorders. * New onset, non-catheter-associated venous thromboembolism within the past 6 months. * Other protocol-defined Inclusion/Exclusion criteria apply.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Local Institution - 0003Tucson, Arizona
- Local Institution - 0007Los Angeles, California
- Local Institution - 0011Grand Rapids, Michigan
- Local Institution - 0004Sioux Falls, South Dakota
- Local Institution - 0013San Antonio, Texas
- Local Institution - 0021Darlinghurst, New South Wales
- Local Institution - 0019Elizabeth Vale, South Australia
- Local Institution - 0017Toronto, Ontario
- Local Institution - 0016Montreal, Quebec
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 17, 2026. Always confirm current availability with the study team.